The Disproportion That Defines This Moment
There is a number that stops every informed person in their tracks when they first encounter it. Congenital heart disease, the most common structural birth defect in the world, affecting one in every one hundred children born in the United States, receives approximately two percent of the National Institutes of Health cardiovascular research budget.
Two percent.
Not because the science is unimportant. Not because the need is not there. But because the public pressure that drives federal research funding has not yet arrived at the scale this condition deserves. Because congenital heart disease has not yet found its moment in the national consciousness the way other conditions have. Because the families living inside this diagnosis are too busy surviving it to march on Washington.
That is where advocates come in. That is where this essay comes in. And that is where the federal government must come in, with urgency, with resources, and with the recognition that the most common birth defect in the world has been waiting long enough.
What the Funding Gap Actually Costs
When people talk about federal research investment, they often speak in abstractions. Dollars. Percentages. Budget line items. What gets lost in that language is what the numbers actually represent in human terms.
Every dollar not invested in CHD research is a question that goes unanswered. Why do some children with the same diagnosis respond differently to the same surgery? What are the long-term neurological effects of infant cardiac surgery and bypass? Why do some CHD survivors develop heart failure in their thirties while others live well into old age? What genetic markers predict the most severe outcomes, and how early can we intervene if we can identify them?
These are not academic questions. They are the questions that determine whether a child who survives their first surgery will need a second one at thirty. Whether a young woman with CHD can safely carry a pregnancy. Whether a man who grew up with a repaired heart will see his grandchildren.
The answers exist. They are waiting inside research that has not been funded.
The History That Proves the Investment Works
We do not have to speculate about whether research investment in congenital heart disease produces results. We have fifty years of evidence that it does.
The surgical techniques that allow children with hypoplastic left heart syndrome to survive were developed through federally supported research. The understanding of cardiac anatomy that guides every pediatric cardiac surgeon today was built through decades of NIH-funded study. The diagnostic tools that allow CHD to be identified before birth, giving families time to prepare and medical teams time to plan, exist because researchers had the funding to develop them.
Every life saved by modern pediatric cardiac surgery is a return on a research investment this country made. The question is not whether the investment works. The question is why we stopped making it at the scale the problem demands.
The Frontiers We Have Not Yet Reached
For all the progress that has been made, the frontiers of CHD research remain vast and largely unexplored. Not because the scientific community lacks curiosity or capability. But because sustained funding at the level required to push those frontiers has not materialized.
Consider what adequately funded CHD research could accomplish in the next decade.
- Genetic research that identifies CHD risk before conception, giving families the information to make informed decisions and giving medicine the opportunity to intervene earlier than ever before
- Longitudinal studies of CHD survivors across their entire lifespan, building the evidence base that adult congenital cardiologists desperately need to provide evidence-driven care
- Neurological research into the cognitive and developmental effects of infant cardiac surgery, so that children who survive their procedures receive the educational and psychological support they need from the earliest possible moment
- Bioengineering advances in prosthetic heart valves and patches designed specifically for growing pediatric hearts, reducing the number of reoperations a child must endure
- Research into the causes of CHD itself, moving us from a field that manages the condition brilliantly toward one that might one day prevent it
- Population health studies that map CHD outcomes against socioeconomic factors, exposing the health equity dimensions of this condition and building the case for targeted intervention in underserved communities
The Health Equity Dimension
Federal research investment in CHD is not only a question of scientific priority. It is a question of justice.
The burden of congenital heart disease does not fall equally across populations. Research has consistently shown that outcomes for CHD patients vary significantly by race, ethnicity, socioeconomic status, and geographic location. Black and Hispanic infants with CHD have historically faced worse surgical outcomes than their white counterparts. Children born into poverty are less likely to receive timely diagnosis and more likely to experience complications from delayed care.
These disparities are not inevitable. They are the product of underinvestment in understanding them. When research funding is insufficient, the questions that get asked first are the ones with the largest, most easily accessible patient populations. The communities carrying the heaviest burden are often the last to be studied and the last to benefit from what is learned.
Federal investment in CHD research must explicitly include the mandate to understand and address these disparities. Not as an afterthought. As a core scientific and moral priority.
What Congress Must Do
The path to meaningful federal investment in CHD research runs directly through Congress. The NIH does not set its own priorities in a vacuum. It responds to legislative direction, to appropriations language, to the political signals sent by the representatives the American people elect. When Congress decides that a condition matters, the funding follows.
What is needed right now is specific, sustained, and bipartisan legislative action. This means:
- A dedicated CHD research funding line within the NIH National Heart, Lung, and Blood Institute budget, with a floor that reflects the prevalence and cost burden of the condition
- Congressional mandates for longitudinal CHD outcome studies that track patients from birth through adulthood, building the evidence base that the field currently lacks
- Funding for the creation and expansion of regional ACHD centers of excellence that serve as both clinical hubs and research institutions
- Legislative requirements that NIH-funded cardiovascular research explicitly include pediatric and congenital populations, ending the historical exclusion of children from research that shapes their care
- Federal support for a national CHD patient registry that enables population-level research and gives policymakers the data they need to make informed investment decisions
- Appropriations language that specifically directs NIH to address racial and socioeconomic disparities in CHD outcomes, with accountability measures and public reporting requirements